Cell penetrating peptides that target many cells types including cells of the retina and cornea with high efficiency are provided herein. These peptides can be used to deliver cargo molecules across a plasma membrane, without the need for chemical conjugation. Compositions and viral vectors comprising these cell-penetrating peptides are also provided. Methods of using the peptides, compositions and viruses to deliver various agents to target cells and tissues are also provided.

A betel leaf extracts composition having bactericidal, antiviral, and neutralization of virus SARS-CoV-2 properties by oral. The bactericidal, antiviral, and SARS-CoV-2 virus-neutralizing efficacy of betel leaf extract/essential oil was increased by the combination with the one or two or more active plant extracts/essential oils ingredients, 4-allylpyrocatechol (APC) ingredient, a mixture of ginger-honey, and a mixture of lemon-kumquat-cinnamon by predefined order and predetermined percentage by weight of each ingredient into an oral cavity delivery agent including a range of gum, confectionery/candy, lozenge, tablet, edible film, oral film, oral solution and oral spray solution.

A betel leaf extracts composition having bactericidal, antiviral, and neutralization of virus SARS-CoV-2 properties by oral. The bactericidal, antiviral, and SARS-CoV-2 virus-neutralizing efficacy of betel leaf extract/essential oil was increased by the combination with the one or two or more active plant extracts/essential oils ingredients, 4-allylpyrocatechol (APC) ingredient, a mixture of ginger-honey, and a mixture of lemon-kumquat-cinnamon by predefined order and predetermined percentage by weight of each ingredient into an oral cavity delivery agent including a range of gum, confectionery/candy, lozenge, tablet, edible film, oral film, oral solution and oral spray solution.

The invention encompasses formulations and methods for the production thereof that permit the delivery of concentrated protein solutions. The inventive methods can yield a lower viscosity liquid formulation or a higher concentration of therapeutic or nontherapeutic proteins in the liquid formulation, as compared to traditional protein solutions.

The invention encompasses formulations and methods for the production thereof that permit the delivery of concentrated protein solutions. The inventive methods can yield a lower viscosity liquid formulation or a higher concentration of therapeutic or nontherapeutic proteins in the liquid formulation, as compared to traditional protein solutions.

This disclosure provides compositions and methods for albumin nanoformulation of Bcl-2 and Bcl-xL inhibitor APG-1252 to suppress and/or inhibit growth of cancer cells (e.g., tumor cells). In particular, the present invention is directed to compositions comprising nanoparticles associated with (e.g., complexed, conjugated, encapsulated, absorbed, adsorbed, admixed) APG-1252, methods for synthesizing such nanoparticles, as well as systems and methods utilizing such nanoparticles (e.g., in diagnostic and/or therapeutic settings). Such nanoparticle formulations of APG-1252 are capable of increasing solubility, protecting against its degradation, reducing platelet toxicity, and expanding (improving) different indications to improve anticancer efficacy in various cancers and cancer metastasis in lymph nodes.

A nanoscale drug carrier capable of crossing the blood-brain barrier. Said carrier can target brain lesions (brain tumors or other neurodegenerative diseases). The targeting drug carrier capable of crossing the blood-brain barrier comprises all-heavy-chain human ferritin or a functional fragments reconstituted structure or a mutant thereof. The manner for crossing the blood-brain barrier of the drug carrier is receptor-mediated transcytosis. The drug carrier provides an effective nanoscale drug carrier for the treatment of brain tumors or other neurodegenerative diseases.

A nanoscale drug carrier capable of crossing the blood-brain barrier. Said carrier can target brain lesions (brain tumors or other neurodegenerative diseases). The targeting drug carrier capable of crossing the blood-brain barrier comprises all-heavy-chain human ferritin or a functional fragments reconstituted structure or a mutant thereof. The manner for crossing the blood-brain barrier of the drug carrier is receptor-mediated transcytosis. The drug carrier provides an effective nanoscale drug carrier for the treatment of brain tumors or other neurodegenerative diseases.

Disclosed herein are reduced viscosity liquid formulations comprising a protein and an excipient compounds. Further disclosed are methods of reducing the viscosity of a liquid formulation comprising a protein, methods of treatment, and methods of improving protein processing.

Disclosed herein are reduced viscosity liquid formulations comprising a protein and an excipient compounds. Further disclosed are methods of reducing the viscosity of a liquid formulation comprising a protein, methods of treatment, and methods of improving protein processing.